- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00199355
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
May 21, 2014 updated by: Kyowa Kirin Co., Ltd.
Placebo-Controlled , Double-Blind , Exploratory Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Adjunctive Therapy to Levodopa]
To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
To establish the efficacy of 20 mg/d and 40mg/d doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
Patients who meet entry criteria will be randomized in a 1:1:1 ratio to double blind treatment with oral doses of 20 or 40mg/d istradefylline or matching placebo.
Patients will be treated for 12 weeks and will have interim visits and end of treatment visit to assess the efficacy and safety of istradefylline.
Study Type
Interventional
Enrollment
75
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- UK Parkinson's Disease Society (UKPDS) brain bank criteria (Step 1 and 2) for PD.
- PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale.
- On levodopa/DCI for at least one year, stable dose in past 4 weeks.
- Currently take at least three doses of levodopa/DCI per day.
- Predictable end of dose wearing off.
- Able to satisfactorily complete Hauser version of a Parkinson's diary.
- Have an average of 120 minutes of OFF time on two 24 hour diaries.
- On a stable regimen of medications being administered within normal therapeutic limits for Parkinson's disease for at least four weeks before randomization.
- Be at least 30 years of age.
Exclusion Criteria:
- Neurosurgical treatment for PD.
- History of psychosis.
- Diagnosis of atypical Parkinsonism or secondary Parkinsonism variant.
- Diagnosis of cancer within 5 years.
- Diagnosis of clinically significant illness of any organ system.
- Mini-mental status examination score of 25 or less.
- Taking any excluded medications.
- History of drug or alcohol abuse or dependence within the past two years.
- History of seizures or neurological malignant syndrome.
- Clinical depression.
- Pregnant or lactating females.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To establish the efficacy of 20 mg/d and 40mg/d doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/DCI.
|
Secondary Outcome Measures
Outcome Measure |
---|
To evaluate change in the Clinical Global Impression - Improvement scale (CGI-I).
|
To evaluate change in the Clinical Global Impression - Severity of Illness scale (CGI-S).
|
To evaluate the efficacy of 20 mg/d and 40mg/d dose of istradefylline for reducing the total hours of OFF time.
|
To evaluate the change in percentage of ON time (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia).
|
To evaluate the change in Unified Parkinson's Disease Rating Scale (UPDRS).
|
To evaluate the safety of 20 mg/d and 40mg/d doses of istradefylline.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (Actual)
March 1, 2006
Study Completion (Actual)
March 1, 2006
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Estimate)
May 23, 2014
Last Update Submitted That Met QC Criteria
May 21, 2014
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Purinergic Antagonists
- Purinergic Agents
- Purinergic P1 Receptor Antagonists
- Adenosine A2 Receptor Antagonists
- Istradefylline
Other Study ID Numbers
- 6002-0406
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
Clinical Trials on Istradefylline (KW-6002)
-
Kyowa Kirin, Inc.CompletedParkinson's DiseaseUnited States
-
Kyowa Kirin, Inc.CompletedParkinson's Disease | Movement Disorder SyndromeUnited States
-
Kyowa Hakko Kirin UK, Ltd.CompletedParkinson's DiseaseUnited Kingdom
-
Kyowa Hakko Kirin Pharma, Inc.Kyowa Kirin Co., Ltd.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
Kyowa Kirin, Inc.CompletedSleep Disorder | Restless Legs SyndromeUnited States
-
Kyowa Kirin Co., Ltd.CompletedParkinson's DiseaseJapan
-
Kyowa Kirin, Inc.CompletedParkinson's DiseaseUnited States
-
Kyowa Kirin, Inc.Kyowa Hakko Kirin UK, Ltd.CompletedParkinson's DiseaseUnited States
-
Kyowa Kirin, Inc.CompletedParkinson's DiseaseUnited States
-
Kyowa Kirin, Inc.Completed